Illumina Inc（ILMN）股票分析ILMNIllumina Inc

Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Illumina Inc is currently a hold. The stock is priced at $269.42, which is below the average analyst price target of $300, indicating potential upside. However, the RSI is at 49.005, suggesting it is neither overbought nor oversold, and insider selling has surged by 17343.19% recently, which raises concerns about future performance. The forward P/E ratio is 40.32, indicating high expectations for future earnings, but the recent trend of insider selling and mixed analyst ratings suggest caution is warranted.

18 analysts cover ILMN: 11 rate it Buy, 6 Hold and 1 Sell. The average price target is 133.54.